Cardiovascular outcomes of vildagliptin in patients with type 2 diabetes mellitus after acute coronary syndrome or acute ischemic stroke

Cardiovascular outcomes of vildagliptin in patients with type 2 diabetes mellitus after acute coronary syndrome or acute ischemic stroke

Abstract Aims/Introduction The cardiovascular (CV) outcomes of vildagliptin – a dipeptidyl peptidase‐4 inhibitor – in patients with type 2 diabetes mellitus after acute coronary syndrome or acute ischemic stroke are unclear. Materials and Methods We analyzed data from the Taiwan National Health Insu...

Full description

Bibliographic Details
Main Authors:	Dong‐Yi Chen, Yan‐Rong Li, Chun‐Tai Mao, Chi‐Nan Tseng, I‐Chang Hsieh, Ming‐Jui Hung, Pao‐Hsien Chu, Chao‐Hung Wang, Ming‐Shien Wen, Wen‐Jin Cherng, Tien‐Hsing Chen
Format:	Article
Language:	English
Published:	Wiley 2020-01-01
Series:	Journal of Diabetes Investigation
Subjects:	Cardiovascular outcome Type 2 diabetes mellitus Vildagliptin
Online Access:	https://doi.org/10.1111/jdi.13078

Similar Items

Mild acute pancreatitis with vildagliptin use
by: Ravikant Saraogi, et al.
Published: (2012-01-01)

EFFECT OF PHARMACOLOGICAL PRECONDITIONING WITH INCRETINOMIMETICS EXENATIDE AND VILDAGLIPTIN ON THE SURVIVAL OF ISCHEMIC TISSUES
by: Alla Tarasova, et al.
Published: (2017-12-01)

Drug fever and acute inflammation from hypercytokinemia triggered by dipeptidyl peptidase‐4 inhibitor vildagliptin
by: Takatoshi Anno, et al.
Published: (2019-01-01)

Nanofibrous insulin/vildagliptin core-shell PLGA scaffold promotes diabetic wound healing
by: Chen-Hung Lee, et al.
Published: (2023-04-01)

Vildagliptin induced cutaneous leukocytoclastic vasculitis: A case report
by: Serhat Sayin, et al.
Published: (2018-03-01)

Vildagliptin: a new oral treatment for type 2 diabetes mellitus
by: Chantal Mathieu, et al.
Published: (2008-12-01)

Vildagliptin Has a Neutral Association With Dementia Risk in Type 2 Diabetes Patients
by: Chin-Hsiao Tseng, et al.
Published: (2021-04-01)

Budget impact of vildagliptin
by: Orietta Zaniolo, et al.
Published: (2008-09-01)

Nanofibrous vildagliptin-eluting stents enhance re-endothelialization and reduce neointimal formation in diabetes: in vitro and in vivo
by: Lee CH, et al.
Published: (2019-09-01)

Comparison of efficacy of add-on therapy of vildagliptin versus pioglitazone among Type 2 Diabetes Mellitus patients inadequately controlled on dual therapy of metformin plus sulfonylurea
by: Kirandeep Kaur
Published: (2014-02-01)

Nanofibrous Vildagliptin/PLGA Membranes Accelerate Diabetic Wound Healing by Angiogenesis
by: Chen-Hung Lee, et al.
Published: (2022-11-01)

Effect of vildagliptin on atherosclerosis progression in high cholesterol –fed male rabbits
by: Sahar A Majeed
Published: (2014-12-01)

Acute Effects of Metformin and Vildagliptin after a Lipid-Rich Meal on Postprandial Microvascular Reactivity in Patients with Type 2 Diabetes and Obesity: A Randomized Trial
by: Alessandra Schiappacassa, et al.
Published: (2020-10-01)

Comparison of empagliflozin and vildagliptin for efficacy and safety in type 2 diabetes mellitus in the Pakistani population
by: Asima Khan, et al.
Published: (2022-08-01)

Determination of the vildagliptin intermediate enantiomer by chiralce-columns
by: Weina LI, et al.
Published: (2017-06-01)

Efficacy and pathogenetic justification for the use of vildagliptin in patients with type 2 diabetes mellitus
by: V.I. Pankiv
Published: (2019-10-01)

Silver Nanoparticle Conjugation-Enhanced Antibacterial Efficacy of Clinically Approved Drugs Cephradine and Vildagliptin
by: Abdulkader Masri, et al.
Published: (2018-11-01)

EDGE study in Russian Federation: efficacy and safety of vildagliptine in comparison with other oral antidiabetic agents in patients with type 2 diabetes mellitus
by: Gagik Radikovich Galstyan
Published: (2013-06-01)

Pathogenetic substantiation and effectiveness of vildagliptin use inpatients with diabetes mellitus type 2
Published: (2009-09-01)

Vildagliptin: the first innovative DDP-4 inhibitor
by: Edvin Villkhauer
Published: (2010-09-01)

Cost Utility Analysis Vildagliptin dan Glimepiride dalam Mencegah Komplikasi Mikrovaskuler menggunakan Model Markov
by: Tri Julia Purnamasari, et al.
Published: (2023-12-01)

Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece
by: Hara Kousoulakou, et al.
Published: (2017-09-01)

Comparison of Vildagliptin-Metformin and Glimepiride-Metformin Treatments in Type 2 Diabetic Patients
by: Hyun Jeong Jeon, et al.
Published: (2011-10-01)

UJI EFEKTIVITAS DAN KEAMANAN KOMBINASI METFORMIN-VILDAGLIPTIN PADA DIABETES MELITUS TIPE 2 DI RSPAL Dr. RAMELAN SURABAYA
by: Dwi Octamy Sari, et al.
Published: (2023-10-01)

Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications
by: Elena Valer'evna Biryukova
Published: (2014-03-01)

Vildagliptin: optimal control in type 2 diabetes mellitus treatment
by: Alexander Sergeevich Ametov
Published: (2015-12-01)

Case Report: Rhabdomyolysis secondary to vildagliptin overdose in a suicidal attempt: A case report and brief literature review
by: Zhijia Tang, et al.
Published: (2022-08-01)

Combined saline and vildagliptin induced M2 macrophage polarization in hepatic injury induced by acute kidney injury
by: Shaimaa N. Amin, et al.
Published: (2023-02-01)

Reliability of protonation constants of vildagliptin dimers by the regression analysis of pH-titration data
by: Meloun Milan, et al.
Published: (2013-07-01)

Chiral Separation of Vildagliptin by Capillary Electrophoresis—The Study of Enantiomeric Complexation
by: Lajos Attila Papp, et al.
Published: (2023-12-01)

Renoprotective effect of vildagliptin following hepatic ischemia/reperfusion injury
by: Iman O. Sherif, et al.
Published: (2020-01-01)

Development of Ecofriendly Derivative Spectrophotometric Methods for the Simultaneous Quantitative Analysis of Remogliflozin and Vildagliptin from Formulation
by: Mahesh Attimarad, et al.
Published: (2021-10-01)

CARDIOPRODUCTIVE EFFECTS OF EXXENATE AMID AND VILDAGLIPTIN INCRETIN MIMETICS IN DOXYRUBRICINE CARDIOMYOPATHY MODELING
by: A. P. TARASOVА, et al.
Published: (2017-09-01)

Vildagliptin Treatment on the Portal Venous Pressure and Hepatosteatosis in Patients with Type 2 Diabetes Mellitus
by: Cumali KARATOPRAK, et al.
Published: (2018-01-01)

SECOND-ORDER DERIVATIVE UV SPECTROPHOTOMETRIC AND RP-HPLC METHODS FOR THE ANALYSIS OF VILDAGLIPTIN AND APPLICATION FOR DISSOLUTION STUDY
by: Amanda Thomas Barden, et al.
Published: (2018-09-01)

Blood pressure and fasting lipid changes after 24 weeks’ treatment with vildagliptin: a pooled analysis in >2,000 previously drug-naïve patients with type 2 diabetes mellitus
by: Evans M, et al.
Published: (2016-08-01)

Neuroprotective Effects of the DPP4 Inhibitor Vildagliptin in In Vivo and In Vitro Models of Parkinson’s Disease
by: Ramesh Pariyar, et al.
Published: (2022-02-01)

Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure
by: van Gilst Wiek H, et al.
Published: (2011-09-01)

Vildagliptin: the known and unknown
by: L. Y. Morgunov
Published: (2016-12-01)

Comparison of Glycemic Variability and Hypoglycemic Events in Hospitalized Older Adults Treated with Basal Insulin plus Vildagliptin and Basal–Bolus Insulin Regimen: A Prospective Randomized Study
by: Sol Batule, et al.
Published: (2022-05-01)